- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03956654
A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer (RibOB)
March 27, 2023 updated by: prof. dr. Hans Wildiers, Universitaire Ziekenhuizen KU Leuven
A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib With Letrozole in Older Women (≥70 Years) With HR+ and HER2- Advanced Breast Cancer (aBC) With no Prior Systemic Therapy for Advanced Disease.
The RibOB study is a prospective, open lable, single arm trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+/HER2- aBC and no prior hormonal treatment for advanced disease (as per approved indication).
Study Overview
Detailed Description
The RibOB study is an observational prospective, open lable single arm phase IV trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+, HER2- advanced breast cancer and no prior hormonal treatment for advanced disease as per the indication approved by the European Medicines Authority (EMA) and as made available by Belgian national authorities in the national health care system.
A total of maximum 150 patients will be enrolled for treatment with Letrozole (2.5 mg once daily) + ribociclib 600 mg (day 1 to 21 in a 28 day cycle), which will continue until disease progression, intolerable toxicity or patient/physician decision to withdraw.
During the study, patients will be continuously evaluated for disease progression as per national standard of care (approximately every 12 weeks radiologically); for safety; and for quality of life and geriatric assessment components including functional status with QoL assessment and CGA at 3 months (+/- 2 weeks) and at 1 year (+/-2 weeks).
Study Type
Observational
Enrollment (Actual)
78
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hans Wildiers, prof. dr.
- Phone Number: 003216346900
- Email: hans.wildiers@uzleuven.be
Study Locations
-
-
-
Leuven, Belgium, B-3000
- UZ Gasthuisberg Leuven
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
70 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
This study will include older women (defined as ≥70 years) with HR+, HER2- advanced breast cancer who had not received any prior hormonal agent for treatment of advanced disease.
It is expected that at least 50% of patients will be older than 75 years.
Description
Inclusion Criteria:
- Patient is a female ≥ 70 years old at the time of informed consent.
- Advanced breast cancer (defined as locoregionally recurrent or metastatic not amenable to curative therapy).
- Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory (defined as ER and/or PgR ≥1% or Allred >2).
- HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test as determined by local laboratory testing according to ASCO-CAP guidelines is necessary.
- Patient has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by local laboratory), preferably tested a maximum of 14 days before enrolment:
- Patient has signed informed consent obtained before any trial-related activities and according to local guidelines.
- Subjects must be able to communicate with the investigator and comply with the requirements of the study procedures.
Exclusion Criteria:
- Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole.
- Patients who received any CDK4/6 inhibitor previously.
- Patient who received any prior systemic antihormonal therapy or chemotherapy for advanced breast cancer.
- Patient is concurrently using other systemic anti-cancer therapy (except bone modifying agents).
- Patient with central nervous system (CNS) metastases and/or documented meningeal carcinomatosis unless they meet ALL the following criteria:
- At least 4 weeks from prior therapy for CNS disease completion (including radiation and/or surgery) to starting the study treatment;
- Clinically stable CNS lesions at the time of study treatment initiation and not receiving steroids and/or enzyme-inducing anti-epileptic medications for the management of brain metastases for at least 2 weeks (radiological confirmation of brain disease status is not necessary).
- Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol: (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).
- Patients who already have or who are at significant risk of developing QTc prolongation are not eligible for the study. This includes patients:
- with long QT syndrome;
- with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias;
- with electrolyte abnormalities (potassium, magnesium, sodium and calcium) that are NCI CTCAE 4.03 grade 2 or higher (for details, see table 10 ). Note: phosphate testing is not mandatory, but should the investigator consider measuring it before enrolment, the same rules may be applied
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 2018-2022
|
Clinical efficacy: Progression-free survival (PFS) (defined as the length of time from the start of treatment and death or progression of disease) as determined by the local investigator using RECIST 1.1 rules.
|
2018-2022
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to treatment failure (TTF)
Time Frame: 2018-2022
|
Efficacy: Time to treatment failure (TTF).
It is defined as time from date of start of treatment to the date of event defined as the first documented progression, death due to any cause or withdrawal from treatment.
|
2018-2022
|
Overall response rate (ORR)
Time Frame: 2018-2022
|
Efficacy: Overall response rate (ORR), for patients with measurable disease as determined locally by investigator according to RECIST 1.1.
It is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.
|
2018-2022
|
Overall Survival (OS)
Time Frame: 2018-2022
|
Efficacy: Overall survival (OS).
It is defined as the length of time from the start of treatment and death from any cause.
|
2018-2022
|
Breast cancer specific survival (BCSS)
Time Frame: 2018-2022
|
Efficacy: Breast cancer specific survival (BCSS).
It is defined as the length of time from the start of treatment and death from breast cancer.
|
2018-2022
|
Adverse events
Time Frame: 2018-2022
|
Safety: Incidence of Adverse Events according to the NCI-CTCAE 4.03 during study treatment and according to the results of baseline CGA evaluation; Number of patients who stop ribociclib before progression ; number of patients needing dose interruption/reduction.
|
2018-2022
|
Treatment discontinuation
Time Frame: 2018-2022
|
Safety: Number of patients who stop ribociclib before progression
|
2018-2022
|
Treatment interruption
Time Frame: 2018-2022
|
Safety: number of patients needing dose interruption
|
2018-2022
|
Treatment reduction
Time Frame: 2018-2022
|
Safety: number of patients needing dose reduction
|
2018-2022
|
PFS / OS
Time Frame: 2018-2022
|
Prediction Modeling I: PFS and OS prognostic model based on clinical/pathologic characteristics
|
2018-2022
|
CGA / QoL
Time Frame: 2018-2022
|
Prediction Modeling II: Baseline CGA and QoL and relation with PFS/OS
|
2018-2022
|
Quality of Life (1)
Time Frame: 2018-2022
|
Evolution of QoL during study treatment: EORTC QLQ-C30 (modified) and EORTC IL15 questionnaires
|
2018-2022
|
Quality of Life (2)
Time Frame: 2018-2022
|
Correlation of baseline QoL with OS
|
2018-2022
|
Quality of Life (3)
Time Frame: 2018-2022
|
Correlation of baseline QoL with toxicity grade III-IV
|
2018-2022
|
Comprehensive Geriatric Assessment
Time Frame: 2018-2022
|
Evolution of CGA during study treatment
|
2018-2022
|
Plasma Biomarker Research (1)
Time Frame: 2018-2022
|
Evolution of potential aging biomarkers during study treatment, and predictive value of baseline aging biomarkers on toxicity, PFS and OS (correcting for the prognostic metastatic index in PFS / OS)
|
2018-2022
|
Plasma Biomarker Research (2)
Time Frame: 2018-2022
|
Predictive capacity of thymidine kinase on toxicity, PFS, OS and RR (correcting for the prognostic metastatic index in PFS, OS and RR).
Thymidine kinase d1 versus d15 drop, and Thymidine kinase d15 level
|
2018-2022
|
Plasma Biomarker Research (3)
Time Frame: 2018-2022
|
Develop a plasma microRNA signature for response to study treatment (pre-dose cycle 3)
|
2018-2022
|
Plasma Biomarker Research (4)
Time Frame: 2018-2022
|
Evaluation of plasma antitumor immunity induction by study treatment at day 15 of cycle 1.
|
2018-2022
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 11, 2018
Primary Completion (Actual)
December 31, 2022
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
April 12, 2019
First Submitted That Met QC Criteria
May 15, 2019
First Posted (Actual)
May 21, 2019
Study Record Updates
Last Update Posted (Actual)
March 29, 2023
Last Update Submitted That Met QC Criteria
March 27, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- s61033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Ribociclib
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Fox Chase Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Hadassah Medical OrganizationUnknownSoft Tissue Sarcoma | LiposarcomaIsrael
-
Novartis PharmaceuticalsNot yet recruiting
-
Nader SanaiNovartis; Barrow Neurological Institute; Ivy Brain Tumor CenterActive, not recruitingGlioblastoma Multiforme | MeningiomaUnited States
-
Assaf-Harofeh Medical CenterUnknownSoft-Tissue Sarcoma | Liposarcomas, Dedifferentiated | Liposarcoma - Well Differentiated | Liposarcoma; Mixed TypeIsrael
-
Children's Hospital Medical Center, CincinnatiNovartisTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Bithalamic High Grade GliomaUnited States